Publicly listed Chinese biopharmaceutical company headquartered in Suzhou, Jiangsu; founded in 2011, it focuses on developing monoclonal antibodies and in 2025 launched China's first domestically developed GLP-1 drug for weight loss and diabetes. Incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange (1801).
相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
Unknown
3
100.0%
暂无批准数据
- Innovent Biologics and Pfizer announced a strategic global licensing and collaboration agreement worth up to $10.5 billion to develop 12 promising early-stage cancer medicines. - The partnership combines Innovent's discovery capabilities with Pfizer's global development expertise, focusing on antibody-drug conjugates and multi-specific antibodies with novel payloads. - Under the agreement, Innovent will receive $650 million upfront and up to $9.85 billion in milestone payments, plus double-digit royalties on approved products. - The collaboration includes co-development and co-commercialization opportunities across diverse oncology programs, with Innovent retaining Greater China rights for select programs.
- Takeda will pay Innovent $1.2 billion upfront, including a $100 million equity investment, for rights to two late-stage oncology medicines worldwide outside Greater China. - IBI363, a potentially first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, will be co-developed globally for non-small cell lung cancer and colorectal cancer with promising results in over 1,200 patients. - IBI343, a next-generation Claudin 18.2-targeting antibody-drug conjugate, has received FDA Fast Track designation for pancreatic cancer and is currently in Phase 3 trials for gastric cancer. - The partnership includes an option for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC, with total potential deal value reaching up to $11.4 billion including milestones and royalties.
- Chinese researchers published Phase III clinical trial results for Mazdutide in the New England Journal of Medicine, marking the world's first GCG/GLP-1 dual receptor agonist for weight management. - The drug demonstrated significant weight-loss effects along with additional metabolic benefits including reductions in waist circumference, blood pressure, blood lipids and uric acid levels. - Mazdutide addresses obesity through dual mechanisms of appetite suppression and metabolic acceleration by targeting both GCG and GLP-1 receptors, offering advantages over single-target therapies. - The breakthrough positions China's drug development capabilities at world-class standards and supports the national Healthy China 2030 initiative amid rising obesity rates.
